Aldeyra's allergic conjunctivitis therapy clears Phase III hurdle

Aldeyra shares rose $2.57 (36%) to $9.71 on Tuesday after the company said both doses of reproxalap (ADX-102) met the primary endpoint in the Phase

Read the full 253 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE